全文获取类型
收费全文 | 1266353篇 |
免费 | 94951篇 |
国内免费 | 1585篇 |
专业分类
耳鼻咽喉 | 16342篇 |
儿科学 | 41064篇 |
妇产科学 | 34974篇 |
基础医学 | 189820篇 |
口腔科学 | 34771篇 |
临床医学 | 117962篇 |
内科学 | 248372篇 |
皮肤病学 | 27312篇 |
神经病学 | 102071篇 |
特种医学 | 47020篇 |
外国民族医学 | 267篇 |
外科学 | 178928篇 |
综合类 | 25756篇 |
现状与发展 | 3篇 |
一般理论 | 569篇 |
预防医学 | 104746篇 |
眼科学 | 28076篇 |
药学 | 92724篇 |
7篇 | |
中国医学 | 2023篇 |
肿瘤学 | 70082篇 |
出版年
2018年 | 13567篇 |
2017年 | 10421篇 |
2016年 | 11368篇 |
2015年 | 13122篇 |
2014年 | 18074篇 |
2013年 | 27565篇 |
2012年 | 37703篇 |
2011年 | 40091篇 |
2010年 | 23141篇 |
2009年 | 22341篇 |
2008年 | 37855篇 |
2007年 | 40531篇 |
2006年 | 40074篇 |
2005年 | 39208篇 |
2004年 | 37652篇 |
2003年 | 36046篇 |
2002年 | 34976篇 |
2001年 | 56112篇 |
2000年 | 57123篇 |
1999年 | 48163篇 |
1998年 | 13437篇 |
1997年 | 12247篇 |
1996年 | 12660篇 |
1995年 | 11926篇 |
1994年 | 11126篇 |
1993年 | 10415篇 |
1992年 | 38242篇 |
1991年 | 37708篇 |
1990年 | 36488篇 |
1989年 | 35310篇 |
1988年 | 32729篇 |
1987年 | 32055篇 |
1986年 | 30550篇 |
1985年 | 28821篇 |
1984年 | 21965篇 |
1983年 | 19211篇 |
1982年 | 11377篇 |
1981年 | 10329篇 |
1979年 | 20969篇 |
1978年 | 15406篇 |
1977年 | 12799篇 |
1976年 | 11853篇 |
1975年 | 12824篇 |
1974年 | 15599篇 |
1973年 | 15376篇 |
1972年 | 14528篇 |
1971年 | 13563篇 |
1970年 | 12794篇 |
1969年 | 12071篇 |
1968年 | 11241篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
R H Green C E Brightling S McKenna B Hargadon N Neale D Parker C Ruse I P Hall I D Pavord 《The European respiratory journal》2006,27(6):1144-1151
There is increasing evidence that the assessment of eosinophilic airway inflammation using induced sputum and measurement of airway hyperresponsiveness provides additional, clinically important information concerning asthma control. The aim of this study was to directly compare the effects of different treatments on these markers in patients with asthma and persistent symptoms, despite the use of low-dose inhaled corticosteroids. A double-blind four-way crossover study was performed, which compared a 1-month treatment with budesonide 400 mug b.i.d., additional formoterol, additional montelukast and placebo in 49 patients with uncontrolled asthma despite budesonide 100 mug b.i.d., with each treatment separated by a 4-week washout period. The change in sputum eosinophil count with formoterol (2.4 to 3.8% change, 0.6-fold reduction, 95% confidence interval (CI) 0.5-0.9) differed significantly from placebo (2.8 to 2.5% change, 1.1-fold reduction, 95% CI 0.7-1.6) and high-dose budesonide (2.7 to 1.6% change, 1.6-fold reduction, 95% CI 1.2-2.2). The effects of montelukast did not differ from placebo. The changes in methacholine airway responsiveness were small and did not differ between treatments. High-dose budesonide had the broadest range of beneficial effects on other outcomes, including symptom scores, morning peak expiratory flow and forced expiratory volume in one second. In conclusion, treatment given in addition to low-dose inhaled corticosteroids results in modest benefits. Formoterol and high-dose budesonide have contrasting effects on eosinophilic airway inflammation. 相似文献
62.
J Müller-Quernheim K I Gaede E Fireman G Zissel 《The European respiratory journal》2006,27(6):1190-1195
An increase in chronic beryllium disease (CBD) has been suggested due to higher industrial use of beryllium alloys. Since occupational CBD is a perfect phenocopy of sarcoidosis, it might be misdiagnosed as sarcoidosis. In the current it was hypothesised that CBD exists in cohorts of sarcoidosis patients. In a prospective case study, sarcoidosis patients were evaluated for potential beryllium exposure. In those patients in whom beryllium exposure was confirmed and beryllium hypersensitivity demonstrated, the diagnosis of sarcoidosis was rejected and corrected to CBD. In 84 patients seen for re-evaluation or making a diagnosis of sarcoidosis, beryllium exposure was recognised and a diagnosis of CBD was made in 34 out of 84 patients. The time lag between clinical diagnosis of sarcoidosis and the final diagnosis of CBD ranged 0-18 yrs (median 3 yrs) and the mean (range) age at time of diagnosis of CBD was 43.9(25-80) yrs. Beryllium-contaminated workplaces causing disease encompassed a wide spectrum of industries and technical trades in which beryllium-exposure is generally not perceived as a health hazard. In conclusion, chronic beryllium disease still belongs to the spectrum of differential diagnoses of granulomatous disorders. 相似文献
63.
C T Gan G P McCann J T Marcus S A van Wolferen J W Twisk A Boonstra P E Postmus A Vonk-Noordegraaf 《The European respiratory journal》2006,28(6):1190-1194
The aim of the current study was to investigate whether alterations in N-terminal pro brain natriuretic peptide (NT-proBNP) reflect changes in right ventricular structure and function in pulmonary hypertension patients during treatment. The study consisted of 30 pulmonary hypertension patients; 15 newly diagnosed and 15 on long-term treatment. NT-proBNP, right heart catheterisation and cardiac magnetic resonance imaging measurements were performed, at baseline and follow-up. There were no significant differences between newly diagnosed patients and those on treatment at baseline or follow-up with respect to NT-proBNP, haemodynamics and right ventricular parameters. Relative changes in NT-proBNP during treatment were correlated to the relative changes in right ventricular end-diastolic volume index (r = 0.59), right ventricular mass index (r = 0.62) and right ventricular ejection fraction (r = -0.81). N-terminal pro brain natriuretic peptide measurements reflect changes in magnetic resonance imaging-measured right ventricular structure and function in pulmonary hypertension patients. An increase in N-terminal pro brain natriuretic peptide over time reflects right ventricular dilatation concomitant to hypertrophy and deterioration of systolic function. 相似文献
64.
Chan C. H. Y Ng E. H. Y Chan C. L W 《世界核心医学期刊文摘》2006,2(6):15-15
目的:评价东部身体-智力-精神(EBMS)群体干预对进行体外受精(IVF)的中国妇女焦虑缓解的作用。设计:随机对照研究。机构:三级辅助生殖机构。受试者:227例接受第1个IVF周期治疗的妇女。干预:干预组(n=69)接受4次EBMS群体咨询,而对照组(n=115)无任何干预。主要观察指标:状态-特质焦虑问卷。结果:与对照组相比,干预组在干预后状态焦虑平均分显著下降。每组移植同样数目的卵子,但干预组没有明显更高妊娠率的倾向。 相似文献
65.
C. M. Crceles J. M. Serrano P. Marín E. Escudero E. Fernndez‐Varn 《Transboundary and Emerging Diseases》2006,53(6):300-304
The pharmacokinetics (PK) of moxifloxacin in healthy white New Zealand rabbits was studied following intravenous (IV) and subcutaneous (SC) administration routes as well as a SC long‐acting poloxamer 407 gel formulation (SC‐P407). Moxifloxacin concentrations were determined by high‐performance liquid chromatography assay with fluorescence detection. Mean half‐life for IV, SC and SC‐P407 routes was 2.15, 5.41 and 11.09 h. Clearance value after IV dosing was 0.78 l/kg/h. After SC administration, the mean absolute bioavailability was 117% and the Cmax was 1.61 ± 0.49 mg/l. After SC‐P407 administration, the bioavailability was 44% and the Cmax 1.83 was ±0.62 mg/l. No adverse effects were observed in any of the rabbits following IV, SC and SC‐P407 administration of moxifloxacin. Minimal inhibitory concentrations of moxifloxacin against different strains of Staphylococcus aureus from different european countries were used to compute the main pharmacodynamic (PD) surrogate markers of efficacy. The high tolerability of this SC‐P407 formulation and the favourable PK behaviour such as the long half‐life, acceptable bioavailability and excellent PK–PD ratios achieved indicate that it is likely to be effective in rabbits. 相似文献
66.
Abstract The pain of cluster headache attacks is severe, excruciating and selectively responsive to subcutaneous sumatriptan. Serious
cardiovascular events attributed to sumatriptan are extremely rare and have most often been reported in patients at significant
cardiovascular risk, or in overt cardiovascular disease. They also have occurred, however, in patients without evidence of
cardiovascular disease. We describe a 42-year-old man with episodic cluster headache without history of coronary artery disease
who was admitted to our coronary care unit for acute myocardial infarction after 3 h of subcutaneous injection of sumatriptan.
During hospitalisation cluster headache attacks were successfully treated with e.v. indomethacin. 相似文献
67.
Antony E. Shrimpton Robert L. Schelper Reinhold P. Linke John Hardy Richard Crook Dennis W. Dickson Takashi Ishizawa Richard L. Davis 《Neuropathology》2007,27(3):228-232
Over 100 mutations in the presenilin‐1 gene (PSEN1) have been shown to result in familial early onset Alzheimer disease (EOAD), but only a relatively few give rise to plaques with an appearance like cotton wool (CWP) and/or spastic paraparesis (SP). A family with EOAD, seizures and CWP was investigated by neuropathological study and DNA sequencing of the PSEN1 gene. Aβ was identified in leptomeningeal vessels and in cerebral plaques. A single point mutation, p.L420R (g.1508T > G) that gives rise to a missense mutation in the eighth transmembrane (TM8) domain of PS1 was identified in two affected members of the family. p.L420R (g.1508T > G) is the mutation responsible for EOAD, seizures and CWP without SP in this family. 相似文献
68.
Lei Li Jürgen Bruns Reinhard E. Friedrich Rainer Schmelzle 《European journal of plastic surgery》2006,29(2):93-96
Adamantinoma of long bones is one of the rarest of malignant bone tumors; it is commonly located in the middle or lower third of the diaphysis of the tibia. A case with multiple occurrences affecting both the tibia and fibula is presented. En bloc resection with wide operative margins was performed, and a large tibial defect of 23 cm was effectively bridged by a revascularized free fibular flap. At 13 months follow-up, there was no sign of local recurrence or metastasis, and the patient was mobile. 相似文献
69.
Costas D Lallas Erik P Castle Richard T Schlinkert Paul E Andrews 《JSLS, Journal of the Society of Laparoendoscopic Surgeons》2006,10(2):135-140
BACKGROUND AND OBJECTIVES: In 1999, our institution began a kidney transplant program with collaboration between the departments of General Surgery/Transplantation and Urology. From the onset, donor nephrectomies were performed laparoscopically and are currently the domain of Urology, which had no prior laparoscopic experience before this undertaking. We reviewed our experience. METHODS: A database of our experience was kept prospectively from June 1999 to November 2004. Records of both donors and recipients were reviewed. Special attention was directed toward our changes in technique and their relationship to outcomes, with emphasis on graft extraction and overall complication rates. RESULTS: We reviewed the records of 205 consecutive procedures. We report excellent donor outcomes, including mean operative time (112 minutes), estimated blood loss (120 mL), and length of stay (2.3 days). Complication (14.1%) and open conversion (1.5%) rates were low. For the recipients, early (98.0%) and 1-year (94.7%) graft survival, and ureteral ischemia (2.4%) rates were also appropriate with contemporary experience. CONCLUSIONS: We report our results on laparoscopic donor nephrectomy in a de novo renal transplant program. Because of this experience, we have ventured into other horizons of urologic laparoscopy and currently produce enough volume to support a laparoscopic fellowship. We feel that a productive donor nephrectomy program can enhance urologic laparoscopic programs and should be taken advantage of when available. 相似文献
70.
Hazel B Breitz Richard E Wendt Michael S Stabin Sui Shen William D Erwin Joseph G Rajendran Janet F Eary Lawrence Durack Ebrahim Delpassand William Martin Ruby F Meredith 《Journal of nuclear medicine》2006,47(3):534-542
166Ho-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonate (DOTMP) is a tetraphosphonate molecule radiolabeled with 166Ho that localizes to bone surfaces. This study evaluated pharmacokinetics and radiation-absorbed dose to all organs from this beta-emitting radiopharmaceutical. METHODS: After two 1.1-GBq administrations of 166Ho-DOTMP, data from whole-body counting using a gamma-camera or uptake probe were assessed for reproducibility of whole-body retention in 12 patients with multiple myeloma. The radiation-absorbed dose to normal organs was estimated using MIRD methodology, applying residence times and S values for 166Ho. Marrow dose was estimated from measured activity retained after 18 h. The activity to deliver a therapeutic dose of 25 Gy to the marrow was determined. Methods based on region-of-interest (ROI) and whole-body clearance were evaluated to estimate kidney activity, because the radiotracer is rapidly excreted in the urine. The dose to the surface of the bladder wall was estimated using a dynamic bladder model. RESULTS: In clinical practice, gamma-camera methods were more reliable than uptake probe-based methods for whole-body counting. The intrapatient variability of dose calculations was less than 10% between the 2 tracer studies. Skeletal uptake of 166Ho-DOTMP varied from 19% to 39% (mean, 28%). The activity of 166Ho prescribed for therapy ranged from 38 to 67 GBq (1,030-1,810 mCi). After high-dose therapy, the estimates of absorbed dose to the kidney varied from 1.6 to 4 Gy using the whole-body clearance-based method and from 8.3 to 17.3 Gy using the ROI-based method. Bladder dose ranged from 10 to 20 Gy, bone surface dose ranged from 39 to 57 Gy, and doses to other organs were less than 2 Gy for all patients. Repetitive administration had no impact on tracer biodistribution, pharmacokinetics, or organ dose. CONCLUSION: Pharmacokinetics analysis validated gamma-camera whole-body counting of 166Ho as an appropriate approach to assess clearance and to estimate radiation-absorbed dose to normal organs except the kidneys. Quantitative gamma-camera imaging is difficult and requires scatter subtraction because of the multiple energy emissions of 166Ho. Kidney dose estimates were approximately 5-fold higher when the ROI-based method was used rather than the clearance-based model, and neither appeared reliable. In future clinical trials with 166Ho-DOTMP, we recommend that dose estimation based on the methods described here be used for all organs except the kidneys. Assumptions for the kidney dose require further evaluation. 相似文献